The Underutilization of Intrathecal Baclofen in Poststroke Spasticity

Aurora Medical Center Summit, Summit, Wisconsin, USA.
Topics in Stroke Rehabilitation (Impact Factor: 1.45). 05/2011; 18(3):195-202. DOI: 10.1310/tsr1803-195
Source: PubMed


Stroke is one of the leading causes of adult disability in the United States, with a reported prevalence of 6.4 million people. Spasticity is one of the clinical features of the upper motor neuron syndrome seen after a stroke. The prevalence of spasticity after a stroke ranges from 17% to 42.6%, and an average of two-thirds of people with spasticity have upper and lower extremity involvement. Oral medications and botulinum neurotoxin injections are current treatments for problematic spasticity. However, these treatments are often limited by side effects or dose ceilings. Intrathecal baclofen (ITB) is a proven method for the management of disabling spasticity from multiple etiologies. Studies have demonstrated improved mobility, activities of daily living, and quality of life in spastic poststroke patients. Despite the benefits of ITB, fewer than 1% of stroke patients with severe disabling spasticity are being treated with ITB. This article will review the prevalence of severe poststroke spasticity and the rate of ITB use and will discuss reasons for its limited use in stroke survivors.

Download full-text


Available from: Nicholas Ketchum, Jun 18, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Assess spinal reflex excitability after increasing intrathecal baclofen (ITB) flow by manipulation of drug concentration and mode of administration. The effect of concentration was assessed by comparing changes in H-reflex (H/M ratio) 1-6h after a 50μg ITB bolus at 50μg/ml concentration administered manually via lumbar puncture (LP, duration 1-2min, n=27) to a 50μg bolus at 500μg/ml concentration programmed through the pump and delivered via intrathecal catheter (IC, duration 10min) above simple continuous dose (25-100μg/day, n=16). The effect of mode of administration was assessed by comparing peak changes in H/M ratio after 50μg IC bolus above simple continuous dose (complex continuous mode, n=27) to simple continuous mode only (n=22) at equivalent daily doses (75-150μg/day). H/M decrease was faster and overall greater after LP than IC bolus (mean 1-h 77% vs. 63%, p=0.012; 1-6h 91% vs. 82%, p<0.001, respectively). H/M ratio also decreased significantly more with complex (91%) than simple continuous mode of administration (78%, p=0.025). Lower ITB concentration and complex continuous mode of administration lead to greater decrease in H/M ratio. Decreased spinal reflex excitability after adjustment of drug and pump parameters to increase ITB flow may result in better clinical response.
    No preview · Article · May 2012 · Clinical Neurophysiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
    No preview · Article · Jun 2012 · Current Protein and Peptide Science
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intrathecal baclofen (ITB) therapy is a treatment for intractable spasticity due to a variety of causes. Continuous intrathecal administration of baclofen, an agonist of the inhibitory neurotransmitter γ-aminobutyric acid, inhibits excitation of motor neurons at the spinal level and thus suppresses spasticity. This therapy was introduced clinically in the Europe and the United States in the 1990s, and was finally approved by the Japanese Ministry of Health, Labour and Welfare in Japan in 2005. Clinical use has been permitted since 2006, and reports of therapeutic efficacy are now appearing in Japan. ITB therapy is a non-destructive treatment that enables administration of baclofen from an implantable pump under the control of a programmer, and represents an outstanding treatment method offering both reversibility and adjustability. Indications for ITB therapy have been expanding in recent years to include not only spasticity, but also various causes dystonia. And ITB therapy can greatly improve activities of daily living and quality of life, and this treatment is attracting attention as a neuromodulatory therapy that also affects metabolic and respiratory functions and even state of consciousness. We here report the surgical methods and therapeutic outcomes for 22 patients who underwent ITB therapy for spastic and dystonic patients in our hospital, together with an investigation of the effects on metabolic and respiratory functions.
    No preview · Article · Aug 2012 · Neurologia medico-chirurgica
Show more